A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Li, Xing; Liu, Kaida; Xing, Lidong; Rubinsky, Boris

doi:10.2478/raon-2023-0044

Abstract

Background

Tumor Treating Fields (TTFields) is a non-invasive modality for cancer treatment that utilizes a specific sinusoidal electric field ranging from 100 kHz to 300 kHz, with an intensity of 1 V/cm to 3 V/cm. Its purpose is to inhibit cancer cell proliferation and induce cell death. Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical application in other types of cancer and gain a better understanding of its mechanisms of action, this review aims to summarize the current research status by examining existing literature on TTFields’ clinical trials and mechanism studies.

Conclusions

Through this comprehensive review, we seek to stimulate novel ideas and provide physicians, patients, and researchers with a better comprehension of the development of TTFields and its potential applications in cancer treatment.

References

Chu K, Dupuy D. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14: 199–208. doi: 10.1038/nrc3672
Open DOI Search in Google Scholar Back to article
Li Y, Wang N, Fan LF, Zhao PF, Li JH, Huang L, et al. Robust electrical impedance tomography for biological application: a mini review. Heliyon 2023; 9: e151195. doi: 10.1016/j.heliyon.2023.e15195
Open DOI Search in Google Scholar Back to article
Zhu FY, Liu W, Li P, Zhao H, Deng X, Wang HL. Electric/magnetic intervention for bone regeneration: a systematic review and network meta-analysis. Tisuue Eng Part B Rev 2023; 29: 217–31. doi: 10.1089/ten.teb.2022.0127
Open DOI Search in Google Scholar Back to article
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res 2004; 64: 3288–95. doi: 10.1158/0008-5472.CAN-04-0083
Open DOI Search in Google Scholar Back to article
Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhakin F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104
Open DOI Search in Google Scholar Back to article
Kirson ED, Dbalý V, Rochlitz C, Tovaryš F, Salzberg M, Palti Y. Treatment of locally advanced solid tumors using alternating electric fields (TTFields) - a translational study. [abstract]. Proceedings: AACR Annual Meeting 2023; April 14–19, 2023; Orlando, FL; Part 1. Cancer Res 2006; 66(8 Suppl): 1233.
Search in Google Scholar Back to article
Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD. Tumor-treating fields: a fourth modality in cancer treatment. Clin Cancer Res, 2018; 24: 266–75. doi: 10.1158/1078-0432.CCR-17-1117
Open DOI Search in Google Scholar Back to article
Kirson ED, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman RS, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis 2009; 26: 633–40. doi: 10.1007/s10585-009-9262-y
Open DOI Search in Google Scholar Back to article
Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Ann N Y Acad Sci 2013; 1291: 86–95. doi: 10.1111/nyas.12112
Open DOI Search in Google Scholar Back to article
Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48: 2192–202. doi: 10.1016/j.ejca.2012.04.011
Open DOI Search in Google Scholar Back to article
Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol 2016; 18: 1338–49. doi: 10.1093/neuonc/now182
Open DOI Search in Google Scholar Back to article
Leal T, Bueno R, Havel L, Ward J. Tumor treating fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study. [abstract]. J Thorac Oncol 2021; 16: S651. P82.01. doi: 10.1016/j.jtho.2021.01.1192
Open DOI Search in Google Scholar Back to article
Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. Tumor treating field concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase III LUNAR study. [abstract]. ESMO, October 2018. Ann Oncol 2018, 29: viii543. doi: 10.1093/annonc/mdy292.120
Open DOI Search in Google Scholar Back to article
Weinberg U, Farber O, Giladi M, Bomzon Z, Kirson ED. TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study. [abstract]. ESMO, April 2017. Ann Oncol 2017; 28: ii51. doi: 10.1093/annonc/mdx091.065
Open DOI Search in Google Scholar Back to article
Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A Phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer 2013; 81: 445–50. doi: 10.1016/j.lungcan.2013.06.025
Open DOI Search in Google Scholar Back to article
Vergote I, VonMoos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. Gynecol Oncol 2018; 150: 471–7. doi: 10.1016/j.ygyno.2018.07.018
Open DOI Search in Google Scholar Back to article
Picozzi V, Macarulla T, Becerra C, Dragovich T. Front-line treatment of locally advanced pancreatic adenocarcinoma with tumour treating fields concomitant with gemcitabine and nab-paclitaxel: the phase 3 PANOVA-3 study. [abstract]. ESMO, Jun 2022. P-120. Ann Oncol 2022; 33: S292. doi: 10.1016/j.annonc.2022.04.210
Open DOI Search in Google Scholar Back to article
Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopz-Martin J, Kung M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology 2019; 19: 64–72. doi: 10.1016/j.pan.2018.10.004
Open DOI Search in Google Scholar Back to article
Giladi M, Schneiderman RS, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. Pancreatology 2014; 14: 54–63. doi: 10.1016/j.pan.2013.11.009
Open DOI Search in Google Scholar Back to article
Leonard F, Kelly J. Clinical value of TTFields treatment in mesothelioma using ASCO and ESMO frameworks. Int J Radiat Oncol Biol Phys 2019; 105: E545–6. doi: 10.1016/j.ijrobp.2019.06.1271
Open DOI Search in Google Scholar Back to article
Mumblat H, Martinez-Conde A, Braten O, Munster M, Dor-On E, Schneiderman RS, et al. Tumor treating fields (TTFields) downregulate the Fanconi anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical model. Lung Cancer 2021; 160: 99–110. doi: 10.1016/j.lungcan.2021.08.011.
Open DOI Search in Google Scholar Back to article
Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019; 20: 1702–9. doi: /10.1016/S1470-2045(19)30532-7.
Open DOI Search in Google Scholar Back to article
Grosu A, Touchefeu Y, Brunner T, Gkika E, Thimme R, Cubillo A. Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): interim safety analysis. [abstract]. P-215. ESMO, Jul 2020. Ann Oncol 2020; 31: S160. doi: 10.1016/j.annonc.2020.04.297
Open DOI Search in Google Scholar Back to article
Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One 2015; 10: 0125269. doi: 10.1371/journal.pone.0125269
Open DOI Search in Google Scholar Back to article
Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep 2015; 5: 18046. doi: 10.1038/srep18046
Open DOI Search in Google Scholar Back to article
Wang XB, Vykoukal J, Becker FF, Gascoyne PRC. Separation of polystyrene microbeads using dielectrophoretic/gravitational field-flow-fractionation. Biophys J 1998; 74: 2689–701. doi: 10.1016/S0006-3495(98)77975-5
Open DOI Search in Google Scholar Back to article
Pethig R. Review article – dielectrophoresis: status of the theory, technology, and applications. Biomicrofluidics 2010; 4: 022811. doi: 10.1063/1.3456626.
Open DOI Search in Google Scholar Back to article
Tuszynski JA, Wenger C, Friesen DE, Preto J. An overview of sub-cellular mechanisms involved in the action of TTFields. Int J Environ Res Public Health 2016; 13: 1128. doi: 10.3390/ijerph13111128
Open DOI Search in Google Scholar Back to article
Li X, Yang F, Rubinsky B. A theoretical study on the biophysical mechanisms by which tumor treating fields affect tumor cells during mitosis. IEEE Trans Biomed Eng 2020; 67: doi: 2594–602. 10.1109/TBME.2020.2965883
Open DOI Search in Google Scholar Back to article
Karanam NK, Ding L, Aroumougame A, Story MD. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. Transl Res 2020; 217: 33–46. doi: 10.1016/j.trsl.2019.10.003
Open DOI Search in Google Scholar Back to article
Kessler A, Frömbling GE, Gross F, Hahn M, Dzokou W, Ernestus RI, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. Cell Death Discov 2018; 4: 77. doi: 10.1038/s41420-018-0079-9
Open DOI Search in Google Scholar Back to article
Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys 2009; 9: 1. doi: 10.1186/1756-6649-9-1
Open DOI Search in Google Scholar Back to article
Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci 2007; 104: 10152–7. doi: 10.1073/pnas.0702916104
Open DOI Search in Google Scholar Back to article
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clinic Oncol 1999; 17: 2572–8. doi: 10.1200/jco.1999.17.8.2572
Open DOI Search in Google Scholar Back to article
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J med 2005; 352: 987–96. doi: 10.1056/NEJMoa043330
Open DOI Search in Google Scholar Back to article
Benson L. Tumor treating fields technology: alternating electric field therapy for the treatment of solid tumors. Semin Oncol Nurs 2018; 34: 137–50. doi: 10.1016/j.soncn.2018.03.005
Open DOI Search in Google Scholar Back to article
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015; 314: 2535–43. doi: 10.1001/jama.2015.16669
Open DOI Search in Google Scholar Back to article
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 2017; 318: 2306–16. doi: 10.1001/jama.2017.18718
Open DOI Search in Google Scholar Back to article
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016; 893: 1–19. doi: 10.1007/978-3-319-24223-1_1
Open DOI Search in Google Scholar Back to article
Grosso F Mądrzak J, Crinò L, Chella A, Weinberg U, Ceresoli GL. STELLAR – a phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. J Thorac Oncol 2016; 11: S147–S50. doi: 10.1016/S1556-0864(16)30322-7
Open DOI Search in Google Scholar Back to article
Ceresoli Gl, et al; NovoCure Ltd. Safety and efficacy of TTFields (150 kHz) concomitant with Pemetrexed and cisplatin or carboplatin in malignant pleural mesothelioma (STELLAR). ClinicalTrials.gov. Identifier (NCT number): NCT02397928. Available at: https://clinicaltrials.gov/ct2/show/NCT02397928?term=NCT+02397928&draw=2&rank=1
Search in Google Scholar Back to article
Ceresoli G, Aerts J, Madrzak J, Dziadziuszko R, Ramlau R, Cedres S, et al. STELLAR: final results of a Phase 2 Trial of TTFields with chemotherapy for first-line treatment of malignant pleural mesothelioma. [abstract]. VIII641. ESMO, Oct 2018. J Thorac Oncol 2018; 13(Suppl 8): S397–8. doi: 10.1093/annonc/mdy301.001.
Open DOI Search in Google Scholar Back to article
Pless M, et al; NovoCure Ltd. NovoTTF-100L in combination with pemetrexed (Alimta^®) for advanced non-small cell lung cancer. ClinicalTrials.gov. Identifier (NCT number): NCT00749346. Available at: https://clinicaltrials.gov/ct2/show/record/NCT00749346?term=NCT+00749346&draw=2&rank=1
Search in Google Scholar Back to article
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2023; 41: 2682–90. doi: 10.1200/JCO.22.02546
Open DOI Search in Google Scholar Back to article
NovoCure GmbH. Effect of tumor treating fields (TTFields) (150 kHz) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR). ClinicalTrials.gov. Identifier (NCT number): NCT02973789. Available at: https://clinicaltrials.gov/ct2/show/NCT02973789?term=NCT02973789&draw=2&rank=1
Search in Google Scholar Back to article
Voloshin T, Munster M, Blatt R, Shteingauz A, Roberts PC, Schmelz EM, et al. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. Int J Cancer 2016; 139: 2850–8. doi: 10.1002/ijc.30406
Open DOI Search in Google Scholar Back to article
Lok E, San P, White V, Liang O, Widick PC, Reddy SP, et al. Tumor treating fields for ovarian aarcinoma: a modeling study. Adv Radiat Oncol 2021; 6: 100716. doi: 10.1016/j.adro.2021.100716
Open DOI Search in Google Scholar Back to article
Grosso F, Pless M, Ceresoli GL. Safety of tumour treating fields delivery to the torso: meta analysis from TTFields clinical trials. Ann Onco 2019; 30: v187–v8. doi: 10.1093/annonc/mdz244.059
Open DOI Search in Google Scholar Back to article
Kirson ED, Giladi M, Bomzon Z, Weinberg U, Farber O. INNOVATE-3: phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer. J Clin Oncol 2018; 36: TPS5614–TPS5614. doi: 10.1200/JCO.2018.36.15_suppl.TPS5614
Open DOI Search in Google Scholar Back to article
Sessa C, et al; NovoCure Ltd. An open label pilot study of the novoTTF-100L(O) system (NovoTTF Therapy) (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT02244502. Available at: https://clinicaltrials.gov/ct2/show/NCT02244502?term=TTFields&cond=ovarian+cancer&draw=2&rank=2
Search in Google Scholar Back to article
Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014; 15: 799–808. doi: 10.1016/S1470-2045(14)70244-X
Open DOI Search in Google Scholar Back to article
Vergote I, et al; NovoCure Ltd. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50/GOG-3029/INNOVATE-3). ClinicalTrials.gov. Identifier (NCT number): NCT03940196. Available at: https://clinicaltrials.gov/ct2/history/NCT03940196?V_82=View#StudyPageTop
Search in Google Scholar Back to article
Vergote IB, Copeland L, Monk BJ, Coleman RL, Cibula D, Sehouli J, et al. Tumour treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase III INNOVATE-3/ENGOT-ov50 study. [abstract]. ESMO, Oct 2019. Ann of Oncol 2019; 30(Suppl 5): v431. doi: 10.1093/annonc/mdz250.067
Open DOI Search in Google Scholar Back to article
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319–34. doi: 10.1038/nrclinonc.2015.53
Open DOI Search in Google Scholar Back to article
Carbonero RG, Guillen C, Benavides-Orgaz M, Gallego-Plazas J, Rivera F; NovoCure Ltd. A phase II study of TTFields (150 kHz) concomitant with gemcitabine and TTFields concomitant with gemcitabine plus nab-paclitaxel for front-line therapy of advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT01971281. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT01971281
Search in Google Scholar Back to article
NovoCure Ltd. Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma. ClinicalTrials.gov. Identifier (NCT number): NCT03377491. Available at: https://clinicaltrials.gov/ct2/show/NCT03377491?term=TTFields&cond=Pancreatic+Adenocarcinoma&draw=2&rank=2
Search in Google Scholar Back to article
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492
Open DOI Search in Google Scholar Back to article
Davidi S, Jacobovitch S, Shteingauz A, Martinez-Conde A, Braten O, Tempel-Brami C, et al. Tumor treating Fields (TTFields) concomitant with sorafenib inhibit hepatocellular carcinoma in iitro and in vivo. Cancers 2022; 14: 2959. doi: 10.3390/cancers14122959
Open DOI Search in Google Scholar Back to article
NovoCure Ltd. HEPANOVA: A Phase II Trial of tumor treating fields (TTFields, 150khz) concomitant with sorafenib for advanced hepatocellular carcinoma (HCC). ClinicalTrials.gov. Identifier (NCT number): NCT03606590. Available at: https://clinicaltrials.gov/ct2/show/NCT03606590
Search in Google Scholar Back to article
Gkikka E, Touchefeu Y, Mercade TM, Gracián AC, Brunner T, Schultheiß M, et al. HEPANOVA: final efficacy and safety results from a phase 2 study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC). [abstract]. IHPBA 15th World Congress. New York, USA, 30 March - 2 April 2022. HPB 2022; 24(Suppl 1): S262–S3. doi: 10.1016/j.hpb.2022.05.551
Open DOI Search in Google Scholar Back to article
Jones TH, Song JW, Abushahin L. Tumor treating fields: an emerging treatment modality for thoracic and abdominal cavity cancers. Transl Oncol 2022; 15: 101296. doi: 10.1016/j.tranon.2021.101296
Open DOI Search in Google Scholar Back to article
Tsimberidou AM et al; MD Anderson Cancer Center. Phase I Study of tumor treating fields (TTF) in combination with cabozantinib, or with atezolizumab and Nab-paclitaxel in patients with advanced solid tumors involving the abdomen or thorax. ClinicalTrials.gov. Identifier (NCT number): NCT05092373. Available at: https://clinicaltrials.gov/ct2/show/NCT05092373?term=TTFields&cond=Breast+Cancer&draw=2&rank=1
Search in Google Scholar Back to article
Tuszynski J, Luchko T, Carpenter E, Crawford E. Results of molecular dynamics computations of the structural and electrostatic properties of tubulin and their consequences for microtubules. J Comput Theor Nanosci 2004; 1: 392–7. doi: 10.1166/jctn.2004.042
Open DOI Search in Google Scholar Back to article
Mershin A, Kolomenski AA, Schuessler HA, Nanopoulos DV. Tubulin dipole moment, dielectric constant and quantum behavior: computer simulations, experimental results and suggestions. Biosystems 2004; 77: 73–85. doi: 10.1016/j.biosystems.2004.04.003
Open DOI Search in Google Scholar Back to article
Mungan CE, Lasinski A. Motion of an electric dipole in a static electromagnetic field. Lat Am J Phys Educ 2008; 2: 192–4.
Search in Google Scholar Back to article
Riley MM, San P, Lok E, Swanson KD, Wong ET. The clinical application of tumor treating fields Therapy in Glioblastoma. J Vis Exp 2019; 146: e58937. doi: 10.3791/58937
Open DOI Search in Google Scholar Back to article
Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. Cell Death Dis 2017; 8: e2753. doi: 10.1038/cddis.2017.171
Open DOI Search in Google Scholar Back to article
Zhao Y, Zhang G. Elucidating the mechanism of 200 kHz tumor treating fields with a modified DEP theory. 2018 IEEE International Symposium on Signal Processing and Information Technology (ISSPIT). 6–8 Dec 2018, Luisville, USA. pp 1–5. doi: 10.1109/ISSPIT.2018.8705145
Open DOI Search in Google Scholar Back to article
Wick W. TTFields: where does all the skepticism come from? Neuro-Oncol 2016; 18: 303–5. doi: 10.1093/neuonc/now012
Open DOI Search in Google Scholar Back to article
Gagliardi LJ. Electrostatic force in prometaphase, metaphase, and anaphase-A chromosome motions. Physi Rev E 2002; 66: 011901. doi: 10.1103/PhysRevE.66.011901
Open DOI Search in Google Scholar Back to article
Gagliardi LJ. Electrostatic force generation in chromosome motions during mitosis. J Electrost 2005; 63: 309–327. doi: 10.1016/j.elstat.2004.09.007
Open DOI Search in Google Scholar Back to article
Gagliardi LJ. Microscale electrostatics in mitosis. J Electrost 2002; 54: 219–32. doi: 10.1016/S0304-3886(01)00155-3
Open DOI Search in Google Scholar Back to article
Stracke R, Böhm KJ, Wollweber L, Tuszynski JA, Unger E. Analysis of the migration behaviour of single microtubules in electric fields. Biochem Biophys Res Commun 2002; 293: 602–9. doi: 10.1016/S0006-291X(02)00251-6
Open DOI Search in Google Scholar Back to article
Zhang Y, Chen X. Blood cells separation microfluidic chip based on dielectrophoretic force. J Braz Soc Mech Sci Eng 2020; 42: 1–11. doi: 10.1007/s40430-020-02284-8
Open DOI Search in Google Scholar Back to article
Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT, et al. Tumor treating fields: at the crossroads between physics and biology for cancer treatment. Front Oncol 2020; 10: 575992. doi: 10.3389/fonc.2020.575992
Open DOI Search in Google Scholar Back to article
Alexander S, Rieder CL. Chromosome motion during attachment to the vertebrate spindle: initial saltatory-like behavior of chromosomes and quantitative analysis of force production by nascent kinetochore fibers. J Cell Biol 1991; 113: 805–15. doi: 10.1083/jcb.113.4.805
Open DOI Search in Google Scholar Back to article
Li X, Yang F, Gao B, Yu X, Rubinsky B. A theoretical analysis of the effects of tumor-treating electric fields on single cells. Bioelectromagnetics 2020; 41: 438–46. doi: 10.1002/bem.22274
Open DOI Search in Google Scholar Back to article
Berkelmann L, Bader A, Meshksar S, Dierks A, Hatipoglu Majernik G, Krauss JK, et al. Tumour-treating fields (TTFields): investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. Sci Rep 2019; 9: 7362. doi: 10.1038/s41598-019-43621-9
Open DOI Search in Google Scholar Back to article
Geng T, Lu C. Microfluidic electroporation for cellular analysis and delivery. Lab Chip 2013; 13: 3803–21. doi: 10.1039/C3LC50566A
Open DOI Search in Google Scholar Back to article
Chang E, Patel CB, Pohling C, Young C, Song J, Flores TA, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. Cell Death Discov 2018; 4: 113. doi: 10.1038/s41420-018-0130-x
Open DOI Search in Google Scholar Back to article
Kurtz-Nelson EC, Rea HM, Petriceks AC, Hudac CM, Wang T, Earl RK, et al. Alternating electric fields (TTFields) activate Cav1. 2 channels in human glioblastoma cells. Cancers 2019; 11: 110. doi: 10.3390/cancers11010110
Open DOI Search in Google Scholar Back to article
Gal V, Martin S, Bayley P. Fast disassembly of microtubules induced by Mg²⁺ or Ca²⁺. Biochem Biophys Res Commun 1988; 155: 1464–1470. doi: 10.1016/S0006-291X(88)81306-8
Open DOI Search in Google Scholar Back to article
Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman RSet al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother 2020; 69: 1191–204. doi: 10.1007/s00262-020-02534-7
Open DOI Search in Google Scholar Back to article
Tanzhu G, Chen L, Xiao G, Shi W, Peng H, Chen D, et al. The schemes, mechanisms and molecular pathway changes of tumor treating fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell Death Discov 2022; 8: 416. doi: 10.1038/s41420-022-01206-y
Open DOI Search in Google Scholar Back to article
Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, et al. Tumor treating fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest 2022; 132: e149258. doi: 10.1172/JCI149258
Open DOI Search in Google Scholar Back to article
Shteingauz A, Porat Y, Voloshin T, Schneiderman RS, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to tumor treating fields (TTFields). Cell Death Dis 2018; 9: 1074. doi: 10.1038/s41419-018-1085-9
Open DOI Search in Google Scholar Back to article
Kim EH, Jo Y, Sai S, Park MJ, Kim JY, Kim JS, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. Oncogene 2019; 38: 6630–46. doi: 10.1038/s41388-019-0882-7
Open DOI Search in Google Scholar Back to article
Lee YJ, Cho JM, Sai S, Oh JY, Park JA, Oh SJ, et al. 5-Fluorouracil as a tumor-treating field-sensitizer in colon cancer therapy. Cancers 2019; 11: 1999. doi: 10.3390/cancers11121999
Open DOI Search in Google Scholar Back to article
Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, et al. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep 2019; 9: 18699. doi: 10.1038/s41598-019-55296-3
Open DOI Search in Google Scholar Back to article

A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

Abstract

Background

Conclusions

Paradigm

My account